1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Grady WM and Carethers JM: Genomic and
epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kim KY, Cha IH, Ahn JB, Kim NK, Rha SY,
Chung HC, Roh JK and Shin SJ: Estimating the adjuvant chemotherapy
effect in elderly stage II and III colon cancer patients in an
observational study. J Surg Oncol. 107:613–618. 2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kolligs FT, Bommer G and Göke B:
Wnt/beta-catenin/tcf signaling: A critical pathway in
gastrointestinal tumorigenesis. Digestion. 66:131–144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Gupta N, Schmitt F, Grebhardt S and Mayer
D: Beta-catenin is a positive regulator of estrogen receptor-alpha
function in breast cancer cells. Cancers (Basel). 3:2990–3001.
2011. View Article : Google Scholar
|
7
|
Yuan G, Wang C, Ma C, Chen N, Tian Q,
Zhang T and Fu W: Oncogenic function of DACT1 in colon cancer
through the regulation of β-catenin. PLoS One. 7:e340042012.
View Article : Google Scholar
|
8
|
Satow R, Shitashige M, Jigami T, Fukami K,
Honda K, Kitabayashi I and Yamada T: β-catenin inhibits
promyelocytic leukemia protein tumor suppressor function in
colorectal cancer cells. Gastroenterology. 142:572–581. 2012.
View Article : Google Scholar
|
9
|
Rowan AJ, Lamlum H, Ilyas M, Wheeler J,
Straub J, Papadopoulou A, Bicknell D, Bodmer WF and Tomlinson IP:
APC mutations in sporadic colorectal tumors: A mutational ‘hotspot’
and interdependence of the ‘two hits’. Proc Natl Acad Sci USA.
97:3352–3357. 2000. View Article : Google Scholar
|
10
|
Angers S and Moon RT: Proximal events in
Wnt signal transduction. Nat Rev Mol Cell Biol. 10:468–477.
2009.PubMed/NCBI
|
11
|
Mills CN, Nowsheen S, Bonner JA and Yang
ES: Emerging roles of glycogen synthase kinase 3 in the treatment
of brain tumors. Front Mol Neurosci. 4:472011. View Article : Google Scholar
|
12
|
Cohen P and Goedert M: GSK3 inhibitors:
Development and therapeutic potential. Nat Rev Drug Discov.
3:479–487. 2004. View
Article : Google Scholar : PubMed/NCBI
|
13
|
Cross DA, Alessi DR, Cohen P, Andjelkovich
M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by
insulin mediated by protein kinase B. Nature. 378:785–789. 1995.
View Article : Google Scholar : PubMed/NCBI
|
14
|
He Y, Wang J, Liu X, Zhang L, Yi G, Li C,
He X, Wang P and Jiang H: Toosendanin inhibits hepatocellular
carcinoma cells by inducing mitochondria-dependent apoptosis.
Planta Med. 76:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Tang MZ, Wang ZF and Shi YL: Involvement
of cytochrome c release and caspase activation in
toosendanin-induced PC12 cell apoptosis. Toxicology. 201:31–38.
2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yu JC, Min ZD and Ip NY: Melia toosendan
regulates PC12 Cell differentiation via the activation of protein
kinase A and extracellular signal-regulated kinases. Neurosignals.
13:248–257. 2004. View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhang B, Wang ZF, Tang MZ and Shi YL:
Growth inhibition and apoptosis-induced effect on human cancer
cells of toosendanin, a triterpenoid derivative from chinese
traditional medicine. Invest New Drugs. 23:547–553. 2005.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Clardy J and Walsh C: Lessons from natural
molecules. Nature. 432:829–837. 2004. View Article : Google Scholar : PubMed/NCBI
|
19
|
Mishra BB and Tiwari VK: Natural products:
An evolving role in future drug discovery. Eur J Med Chem.
46:4769–4807. 2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Ju J, Qi Z, Cai X, Cao P, Huang Y, Wang S,
Liu N and Chen Y: The apoptotic effects of toosendanin are
partially mediated by activation of deoxycytidine kinase in HL-60
cells. PLoS One. 7:e525362012. View Article : Google Scholar
|
21
|
Shi YL and Li MF: Biological effects of
toosendanin, a triterpenoid extracted from Chinese traditional
medicine. Prog Neurobiol. 82:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
22
|
Tamgue O, Chai CS, Hao L, Zambe JC, Huang
WW, Zhang B, Lei M and Wei YM: Triptolide inhibits histone
methyltransferase EZH2 and modulates the expression of its target
genes in prostate cancer cells. Asian Pac J Cancer Prev.
14:5663–5669. 2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ji AJ, Liu SL, Ju WZ and Huang XE:
Anti-proliferation effects and molecular mechanisms of action of
tetramethypyrazine on human SGC-7901 gastric carcinoma cells. Asian
Pac J Cancer Prev. 15:3581–3586. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Song YA, Park YL, Kim KY, Myung E, Chung
CY, Cho SB, Lee WS, Jung YD, Kweon SS and Joo YE: RON is associated
with tumor progression via the inhibition of apoptosis and cell
cycle arrest in human gastric cancer. Pathol Int. 62:127–136. 2012.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Arends MJ, Morris RG and Wyllie AH:
Apoptosis. The role of the endonuclease. Am J Pathol. 136:593–608.
1990.PubMed/NCBI
|
26
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Gambi N, Tramontano F and Quesada P:
Poly(ADPR)polymerase inhibition and apoptosis induction in
cDDP-treated human carcinoma cell lines. Biochem Pharmacol.
75:2356–2363. 2008. View Article : Google Scholar : PubMed/NCBI
|
28
|
Burlacu A: Regulation of apoptosis by
Bcl-2 family proteins. J Cell Mol Med. 7:249–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
29
|
Lu W, Jia G, Meng X, Zhao C, Zhang L, Ren
Y, Pan H and Ni Y: Beta-catenin mediates the apoptosis induction
effect of celastrol in HT29 cells. Life Sci. 91:279–283. 2012.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Li J and Zhou BP: Activation of β-catenin
and Akt pathways by Twist are critical for the maintenance of EMT
associated cancer stem cell-like characters. BMC Cancer. 11:492011.
View Article : Google Scholar
|
31
|
Cai C and Zhu X: The Wnt/β-catenin pathway
regulates self-renewal of cancer stem-like cells in human gastric
cancer. Mol Med Rep. 5:1191–1196. 2012.PubMed/NCBI
|
32
|
Nuñez F, Bravo S, Cruzat F, Montecino M
and De Ferrari GV: Wnt/β-catenin signaling enhances
cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer
cells. PLoS One. 6:e185622011. View Article : Google Scholar
|
33
|
Park EJ, Chung HJ, Park HJ, Kim GD, Ahn YH
and Lee SK: Suppression of Src/ERK and GSK-3/β-catenin signaling by
pinosylvin inhibits the growth of human colorectal cancer cells.
Food Chem Toxicol. 55:424–433. 2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
35
|
Kharbanda S, Pandey P, Schofield L,
Israels S, Roncinske R, Yoshida K, Bharti A, Yuan ZM, Saxena S,
Weichselbaum R, et al: Role for Bcl-xL as an inhibitor of cytosolic
cytochrome C accumulation in DNA damage-induced apoptosis. Proc
Natl Acad Sci USA. 94:6939–6942. 1997. View Article : Google Scholar : PubMed/NCBI
|
36
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Li Q, Dashwood WM, Zhong X, Nakagama H and
Dashwood RH: Bcl-2 overexpression in PhIP-induced colon tumors:
Cloning of the rat Bcl-2 promoter and characterization of a pathway
involving beta-catenin, c-Myc and E2F1. Oncogene. 26:6194–6202.
2007. View Article : Google Scholar : PubMed/NCBI
|